We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease

By HospiMedica International staff writers
Posted on 12 Apr 2024
Print article
Image: This study is significant as it addresses a treatment approach that has not been extensively studied before (Photo courtesy of 123RF)
Image: This study is significant as it addresses a treatment approach that has not been extensively studied before (Photo courtesy of 123RF)

There has been a lack of extensive research on the use of drug-coated balloon (DCB)-only strategy for the treatment of de novo left main coronary artery disease, especially in high bleeding risk (HBR) patients. Now, a new study has emphasized the potential benefits of this treatment approach, particularly in HBR patients.

The study conducted at North Karelia Central Hospital-Heart Center (Joensuu, Finland) assessed all consecutive patients who underwent percutaneous coronary intervention (PCI) for a de novo left main coronary artery lesion with a drug-coated balloon (DCB)-only strategy from August 2011 to December 2018. The primary focus was on major adverse cardiovascular events (MACEs), including cardiac death, non-fatal myocardial infarction, and target lesion revascularization (TLR). Patients were categorized into two groups depending on whether lesion preparation met the international consensus group guidelines. The study involved 66 patients, averaging 75±8.6 years in age, with 72% being male and 52% presenting acute coronary syndrome. There were no procedural mortalities or acute closures of the treated left main artery. After 12 months, the overall rates of MACE and TLR were 24% and 6%, respectively. Notably, when lesion preparation conformed to the guidelines, the MACE and TLR rates significantly decreased to 21.2% and 1.9%, respectively.

This study underscores the significance of meticulous lesion preparation in employing a DCB-only strategy for treating de novo left main coronary artery disease. It also highlights the advantages of this method, particularly for HBR patients, by potentially allowing for a shorter duration of dual antiplatelet therapy (DAPT) or eliminating the need for DAPT, thus minimizing bleeding risks. The study’s limitations include its retrospective nature, the small sample size, and a bias toward HBR, elderly, and patients with complex calcified left main lesions. Despite these drawbacks, the findings offer valuable insights into the DCB-only approach for managing left main coronary artery disease, suggesting it is a feasible alternative for HBR patients. This study contributes significantly to interventional cardiology, especially for those focused on PCI strategies for left main coronary artery disease and the care of HBR patients. It advocates for future randomized trials to compare DCB angioplasty with stenting using drug-eluting stents (DESs) to validate these results and further evaluate the advantages and limitations of the DCB-only strategy.

Related Links:
North Karelia Central Hospital-Heart Center 

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Anesthesia Cart
UMGSA-33369-VIL

Print article

Channels

Surgical Techniques

view channel
Image: Ureteral electrothermal injury is visible via histology ex vivo (Photo courtesy of Long et al., doi 10.1117/1.BIOS.1.1.015001)

Minimally Invasive Imaging Technique to Revolutionize Ureteral Injury Detection

Electrothermal ureteral injuries are a frequent complication during pelvic surgery. The ureters, which are delicate tubes carrying urine from the kidneys to the bladder, are especially at risk due to their... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.